78 related articles for article (PubMed ID: 24301913)
1. Effects of cisplatin and panobinostat on human mesothelial (Met-5A) and malignant pleural mesothelioma (MSTO-211H) cells.
Gultekin KE; Yurdakonar MK; Yaman E; Yuce US; Yilmaz A; Alp E; Celik A; Demiroz SM; Onen HI
Genet Mol Res; 2013 Nov; 12(4):5405-13. PubMed ID: 24301913
[TBL] [Abstract][Full Text] [Related]
2. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
Onen HI; Yilmaz A; Alp E; Celik A; Demiroz SM; Konac E; Kurul IC; Menevse ES
Hum Exp Toxicol; 2015 Feb; 34(2):117-26. PubMed ID: 25028262
[TBL] [Abstract][Full Text] [Related]
3. Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells.
Lee YJ; Lee YJ; Im JH; Won SY; Kim YB; Cho MK; Nam HS; Choi YJ; Lee SH
Food Chem Toxicol; 2013 Feb; 52():61-8. PubMed ID: 23146690
[TBL] [Abstract][Full Text] [Related]
4. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
Borchert S; Suckrau PM; Walter RFH; Wessolly M; Mairinger E; Steinborn J; Hegedus B; Hager T; Herold T; Eberhardt WEE; Wohlschlaeger J; Aigner C; Bankfalvi A; Schmid KW; Mairinger FD
Sci Rep; 2020 Oct; 10(1):18677. PubMed ID: 33122816
[TBL] [Abstract][Full Text] [Related]
5. Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma.
Spugnini EP; Cardillo I; Verdina A; Crispi S; Saviozzi S; Calogero R; Nebbioso A; Altucci L; Cortese G; Galati R; Chien J; Shridhar V; Vincenzi B; Citro G; Cognetti F; Sacchi A; Baldi A
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6133-43. PubMed ID: 17062690
[TBL] [Abstract][Full Text] [Related]
6. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
Vandermeers F; Hubert P; Delvenne P; Mascaux C; Grigoriu B; Burny A; Scherpereel A; Willems L
Clin Cancer Res; 2009 Apr; 15(8):2818-28. PubMed ID: 19351772
[TBL] [Abstract][Full Text] [Related]
7. The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1.
Lee KA; Lee YJ; Ban JO; Lee YJ; Lee SH; Cho MK; Nam HS; Hong JT; Shim JH
Int J Mol Med; 2012 Jul; 30(1):21-7. PubMed ID: 22552784
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.
Varin E; Denoyelle C; Brotin E; Meryet-Figuière M; Giffard F; Abeilard E; Goux D; Gauduchon P; Icard P; Poulain L
Carcinogenesis; 2010 Jun; 31(6):984-93. PubMed ID: 20142415
[TBL] [Abstract][Full Text] [Related]
9. Role of transcription factor Sp1 in the quercetin-mediated inhibitory effect on human malignant pleural mesothelioma.
Chae JI; Cho JH; Lee KA; Choi NJ; Seo KS; Kim SB; Lee SH; Shim JH
Int J Mol Med; 2012 Oct; 30(4):835-41. PubMed ID: 22842769
[TBL] [Abstract][Full Text] [Related]
10. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
Littlejohn JE; Cao X; Miller SD; Ozvaran MK; Jupiter D; Zhang L; Rodarte C; Smythe WR
Int J Cancer; 2008 Jul; 123(1):202-8. PubMed ID: 18360826
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
Hartman ML; Esposito JM; Yeap BY; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2010 May; 139(5):1233-40. PubMed ID: 19853261
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability.
Verdina A; Cardillo I; Nebbioso A; Galati R; Menegozzo S; Altucci L; Sacchi A; Baldi A
J Transl Med; 2008 May; 6():27. PubMed ID: 18498639
[TBL] [Abstract][Full Text] [Related]
13. FOXO3a mediates the cytotoxic effects of cisplatin in lung cancer cells.
Liu H; Yin J; Wang C; Gu Y; Deng M; He Z
Anticancer Drugs; 2014 Sep; 25(8):898-907. PubMed ID: 24814195
[TBL] [Abstract][Full Text] [Related]
14. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
[TBL] [Abstract][Full Text] [Related]
15. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
16. Effect of citrate on malignant pleural mesothelioma cells: a synergistic effect with cisplatin.
Zhang X; Varin E; Allouche S; Lu Y; Poulain L; Icard P
Anticancer Res; 2009 Apr; 29(4):1249-54. PubMed ID: 19414371
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G
Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576
[TBL] [Abstract][Full Text] [Related]
18. The epigenetically regulated effects of Wnt antagonists on the expression of genes in the apoptosis pathway in human bladder cancer cell line (T24).
Varol N; Konac E; Onen IH; Gurocak S; Alp E; Yilmaz A; Menevse S; Sozen S
DNA Cell Biol; 2014 Jul; 33(7):408-17. PubMed ID: 24665856
[TBL] [Abstract][Full Text] [Related]
19. The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma.
Stewart JH; Tran TL; Levi N; Tsai WS; Schrump DS; Nguyen DM
J Surg Res; 2007 Jul; 141(1):120-31. PubMed ID: 17574045
[TBL] [Abstract][Full Text] [Related]
20. New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization.
Indovina P; Giorgi F; Rizzo V; Khadang B; Schenone S; Di Marzo D; Forte IM; Tomei V; Mattioli E; D'Urso V; Grilli B; Botta M; Giordano A; Pentimalli F
Oncogene; 2012 Feb; 31(7):929-38. PubMed ID: 21785466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
